Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Abstract 841: The role of C/EBPβ in prostate cancer cell survival.

View through CrossRef
Abstract The C/EBP family of transcription factors regulates cellular differentiation, proliferation, and inflammatory responses. Three isoforms of C/EBPβ are expressed from the same mRNA: the long LAP1 and LAP2 isoforms mediate transcriptional activation whereas the truncated LIP isoform is repressive. C/EBPβ is dysregulated in various malignancies including breast cancer or multiple myeloma however, its role in prostate cancer is not clear. We have recently reported that C/EBP proteins interact directly with DNA bound NF-kB p50 to displace HDAC, thereby de-repressing anti-apoptotic NF-kB target genes (Paz-Priel, et al. 2011). In four AR-positive (LNCaP, LAPC-4, C4-2B and CwR22Rv1) and two AR-negative (PC3, DU-145) cell lines Western blot analysis demonstrates presence of full-length LAP and the N-terminally truncated LIP isoforms of C/EBPβ. DU-145 cells were stably transduced with a panel of 5 C/EBPβ shRNAs (Open Biosystems). Two shRNA effectively reduced C/EBPβ RNA and protein levels and expression of BCL2 and MCL1 RNA and protein were diminished in parallel. Accordingly, DU-145 cells with reduced C/EBPβ showed increased apoptosis in the presence of paclitaxel compared to cells expressing a non targeting shRNA. We designed and generated a dominant-negative C/EBP termed A-C/EBP, containing 21 predominantly acidic amino acids linked to the C/EBPβ leucine zipper in place of the DNA binding basic region. The acidic domain in A-C/EBP mimics DNA, allowing A-C/EBP to hetero-dimerize with C/EBP proteins to interfere with their ability to bind DNA. Indeed co-transfection of A-C/EBP abrogated C/EBP activation of a Bcl2 promoter luciferase reporter. DU-145 or LNCaP cells expressing A-C/EBP or GFP control were exposed to paclitaxel and apoptosis was assessed after 48 hrs. Cells expressing A-CEBP exhibited increased annexin V positivity (6.0% vs. 15.2%, or 6.7% vs. 17.0% for DU-145 or LNCaP, respectively cultured with 3 nM of paclitaxel), indicating that blockage of C/EBP function or reduced C/EBPβ expression is synergistic with chemotherapy. DU-145 cells expressing A-C/EBP regulated by a TET-ON system, or GFP expressing control cells, were subjected to clonogenic assay in the presence or absence of doxycycline. On average, induction of A-C/EBP in DU-145 cells significantly lowered the number of colonies obtained compared with cells cultured without doxycycline (21.3 vs. 39.7 colonies per 100 seeded cell, p<0.02). Control cells, cultured - or + doxycycline formed 40.3 vs. 50.2 colonies per 100 seeded cell. Together our data suggest that C/EBPβ modulates the survival of both androgen-dependent and -independent prostate cancer cells, and that C/EBPβ inhibition may sensitize cells to chemotherapy. Citation Format: David Baraket, Jing Zhang, Theresa Barberi, Alan D. Friedman, Ido Paz-Priel. The role of C/EBPβ in prostate cancer cell survival. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 841. doi:10.1158/1538-7445.AM2013-841
Title: Abstract 841: The role of C/EBPβ in prostate cancer cell survival.
Description:
Abstract The C/EBP family of transcription factors regulates cellular differentiation, proliferation, and inflammatory responses.
Three isoforms of C/EBPβ are expressed from the same mRNA: the long LAP1 and LAP2 isoforms mediate transcriptional activation whereas the truncated LIP isoform is repressive.
C/EBPβ is dysregulated in various malignancies including breast cancer or multiple myeloma however, its role in prostate cancer is not clear.
We have recently reported that C/EBP proteins interact directly with DNA bound NF-kB p50 to displace HDAC, thereby de-repressing anti-apoptotic NF-kB target genes (Paz-Priel, et al.
2011).
In four AR-positive (LNCaP, LAPC-4, C4-2B and CwR22Rv1) and two AR-negative (PC3, DU-145) cell lines Western blot analysis demonstrates presence of full-length LAP and the N-terminally truncated LIP isoforms of C/EBPβ.
DU-145 cells were stably transduced with a panel of 5 C/EBPβ shRNAs (Open Biosystems).
Two shRNA effectively reduced C/EBPβ RNA and protein levels and expression of BCL2 and MCL1 RNA and protein were diminished in parallel.
Accordingly, DU-145 cells with reduced C/EBPβ showed increased apoptosis in the presence of paclitaxel compared to cells expressing a non targeting shRNA.
We designed and generated a dominant-negative C/EBP termed A-C/EBP, containing 21 predominantly acidic amino acids linked to the C/EBPβ leucine zipper in place of the DNA binding basic region.
The acidic domain in A-C/EBP mimics DNA, allowing A-C/EBP to hetero-dimerize with C/EBP proteins to interfere with their ability to bind DNA.
Indeed co-transfection of A-C/EBP abrogated C/EBP activation of a Bcl2 promoter luciferase reporter.
DU-145 or LNCaP cells expressing A-C/EBP or GFP control were exposed to paclitaxel and apoptosis was assessed after 48 hrs.
Cells expressing A-CEBP exhibited increased annexin V positivity (6.
0% vs.
15.
2%, or 6.
7% vs.
17.
0% for DU-145 or LNCaP, respectively cultured with 3 nM of paclitaxel), indicating that blockage of C/EBP function or reduced C/EBPβ expression is synergistic with chemotherapy.
DU-145 cells expressing A-C/EBP regulated by a TET-ON system, or GFP expressing control cells, were subjected to clonogenic assay in the presence or absence of doxycycline.
On average, induction of A-C/EBP in DU-145 cells significantly lowered the number of colonies obtained compared with cells cultured without doxycycline (21.
3 vs.
39.
7 colonies per 100 seeded cell, p<0.
02).
Control cells, cultured - or + doxycycline formed 40.
3 vs.
50.
2 colonies per 100 seeded cell.
Together our data suggest that C/EBPβ modulates the survival of both androgen-dependent and -independent prostate cancer cells, and that C/EBPβ inhibition may sensitize cells to chemotherapy.
Citation Format: David Baraket, Jing Zhang, Theresa Barberi, Alan D.
Friedman, Ido Paz-Priel.
The role of C/EBPβ in prostate cancer cell survival.
[abstract].
In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC.
Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 841.
doi:10.
1158/1538-7445.
AM2013-841.

Related Results

C/EBPβ expression decreases in cervical cancer and leads to tumorigenesis
C/EBPβ expression decreases in cervical cancer and leads to tumorigenesis
Abstract Background Cervical cancer is currently estimated to be the fourth most common cancer among women worldwide and the leading cause of cancer...
Abstract 4602: Clinicopathological and genetic features of prostate cancer in Algerian patients: First report
Abstract 4602: Clinicopathological and genetic features of prostate cancer in Algerian patients: First report
Abstract Background: Prostate cancer is the second most frequent malignancy (after lung cancer) in men worldwide. It is the third most common cancer in men in Algeri...
Abstract 5758: Deletions of olfactomedin 4 gene is associated with progression of prostate cancer
Abstract 5758: Deletions of olfactomedin 4 gene is associated with progression of prostate cancer
Abstract The human olfactomedin 4 gene (OLFM4) encodes an olfactomedin-related glycoprotein, which our group first cloned and characterized in myeloid cells and mapp...
Abstract 1568: The role of CCL2 CCL17 CCL22-CCR4 axis in prostate cancer metastasis
Abstract 1568: The role of CCL2 CCL17 CCL22-CCR4 axis in prostate cancer metastasis
Abstract BACKGROUND: Multiple steps and factors are involved in prostate carcinogenesis and tumor progression. The early studies have found that tumor-associated mac...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Grade Group 1 Prostate Cancer Outcome by Biopsy Grade and Risk Group
Grade Group 1 Prostate Cancer Outcome by Biopsy Grade and Risk Group
ImportanceAdvocates for removing the cancer label from grade group 1 (GG1) prostate cancer detected on biopsy primarily base their argument on the observation that when only GG1 is...
PROSTATE CANCER EPIDEMIOLOGY IN THE EAST KAZAKHSTAN REGION, 2010-2019
PROSTATE CANCER EPIDEMIOLOGY IN THE EAST KAZAKHSTAN REGION, 2010-2019
Relevance: From 2010 to 2019, prostate cancer morbidity increased, and prostate cancer mortality decreased in Kazakhstan. The peak incidence was observed in patients aged 70 years ...
PROSTATE CANCER EPIDEMIOLOGY IN THE EAST KAZAKHSTAN REGION, 2010-2019
PROSTATE CANCER EPIDEMIOLOGY IN THE EAST KAZAKHSTAN REGION, 2010-2019
Relevance: From 2010 to 2019, prostate cancer morbidity increased, and prostate cancer mortality decreased in Kazakhstan. The peak incidence was observed in patients aged 70 years ...

Back to Top